Publications by authors named "Matteo Raviglione"
Article Synopsis
- - Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for patients with Myelodysplastic syndromes (MDS), traditionally evaluated using the International Prognostic Scoring System-Revised (IPSS-R).
- - Recent advancements in next generation sequencing have led to the development of molecular prognostic scores like IPSS-M, which provide more detailed risk assessment for MDS patients.
- - A study analyzing 57 MDS patients showed that nearly half were re-stratified from IPSS-R to IPSS-M, indicating better prognostic value with IPSS-M, particularly highlighting that very high-risk patients had worse post-transplant outcomes, underscoring the importance of molecular data
